Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Benitec Biopharma (BNTC) over the last 6 years, with Jun 2024 value amounting to $50.9 million.

  • Benitec Biopharma's Cash & Equivalents was N/A to $103.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $103.6 million, marking a year-over-year change of. This contributed to the annual value of $50.9 million for FY2024, which is 1953.53% up from last year.
  • As of FY2024, Benitec Biopharma's Cash & Equivalents stood at $50.9 million, which was up 1,953.53% from $2.5 million recorded in FY2023.
  • In the past 5 years, Benitec Biopharma's Cash & Equivalents registered a high of $50.9 million during FY2024, and its lowest value of $2.5 million during FY2023.
  • For the 3-year period, Benitec Biopharma's Cash & Equivalents averaged around $19.1 million, with its median value being $4.1 million (2022).
  • In the last 5 years, Benitec Biopharma's Cash & Equivalents tumbled by 79.45% in 2022 and then surged by 1,953.53% in 2024.
  • Over the past 5 years, Benitec Biopharma's Cash & Equivalents (Yearly) stood at $9.8 million in 2020, then surged by 101.70% to $19.8 million in 2021, then crashed by 79.45% to $4.1 million in 2022, then plummeted by 39.02% to $2.5 million in 2023, then surged by 1,953.53% to $50.9 million in 2024.